Polio eradication

Polio eradication
Centers for Disease Control and Prevention · Public domain · source
Name	Polio eradication
Disease	Poliomyelitis
Pathogen	Poliovirus

Polio eradication

Polio eradication is the international effort to eliminate poliomyelitis caused by wild poliovirus and vaccine-derived poliovirus through coordinated public health campaigns. The initiative involves partnerships among World Health Organization, United Nations International Children's Emergency Fund, Rotary International, Bill & Melinda Gates Foundation, Centers for Disease Control and Prevention and national ministries of health in countries such as India, Pakistan, Afghanistan, Nigeria and Bangladesh. Its aims intersect with global health diplomacy exemplified by events like the Alma-Ata Declaration, the Millennium Development Goals and the Sustainable Development Goals.

History

The modern drive to eliminate poliomyelitis traces to the development of the inactivated poliovirus vaccine by Jonas Salk and the oral attenuated vaccine by Albert Sabin, milestones comparable to breakthroughs like the Smallpox eradication campaign and achievements recognized by the Nobel Prize in Physiology or Medicine. Early 20th-century outbreaks in cities such as New York City and Copenhagen prompted research at institutes like the National Institutes of Health and laboratories associated with Columbia University and Rockefeller University. National immunization programs modeled after successes in United Kingdom, United States, and Sweden informed later global strategies coordinated by World Health Assembly resolutions and guided by stakeholders including Médecins Sans Frontières, Gavi, the Vaccine Alliance, and donor states such as United States and United Kingdom.

Global eradication initiatives

The launch of the Global Polio Eradication Initiative in 1988 united entities like WHO Regional Office for Europe, WHO Regional Office for Africa, UNICEF Supply Division, Rotary International, and financial supporters including the Bill & Melinda Gates Foundation and World Bank. Campaigns have deployed tactics from mass immunization days in India to targeted "mop-up" campaigns in Afghanistan and Pakistan, coordinated with surveillance networks supported by CDC Global Immunization Division and philanthropic partners such as Clinton Foundation affiliates. International law and diplomacy involving bodies like the United Nations Security Council and bilateral agreements have influenced access in conflict zones like Syria and Iraq.

Vaccines and immunization strategies

Immunization strategies rely on vaccines developed by researchers associated with institutions including University of Pittsburgh (Salk) and Rockefeller Institute (Sabin). The principal products include the inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV), with OPV variants produced by manufacturers such as Serum Institute of India and firms in Belgium and Netherlands. Strategies evolved from routine immunization platforms in Bangladesh and Egypt to supplemental immunization activities used in Nigeria and Pakistan, integrating with campaigns for measles and diphtheria reduction and leveraging logistics models from Gavi, the Vaccine Alliance and cold chain systems influenced by UNICEF procurement.

Surveillance and diagnostics

Acute flaccid paralysis surveillance systems established under guidance from WHO and operational support from CDC and national reference laboratories such as Institut Pasteur and Robert Koch Institute detect cases through stool sample testing and environmental surveillance sampling in sewage systems modeled after programs in Israel and Japan. Molecular diagnostics employ sequencing techniques pioneered by groups at Wellcome Trust Sanger Institute and virology labs at Karolinska Institute to distinguish wild poliovirus lineages and vaccine-derived strains, informing responses coordinated with entities like European Centre for Disease Prevention and Control.

Challenges and setbacks

Progress has been impeded by factors including armed conflict in regions such as Syria and Yemen, vaccine hesitancy linked to misinformation spread in media markets including Pakistan and Nigeria, and logistical barriers in remote regions like parts of Democratic Republic of the Congo and Somalia. Attacks on health workers, politicization involving actors such as Taliban elements, and supply issues related to manufacturing in countries like India and regulatory disputes with agencies such as Drug Controller General of India created setbacks comparable to obstacles faced during Ebola virus epidemic in West Africa. The emergence of circulating vaccine-derived poliovirus required adjustments similar to responses to novel outbreaks managed by WHO and national public health institutes.

Regional progress and case studies

South Asia: India achieved interruption of wild poliovirus transmission after intensive campaigns involving National polio surveillance project partners and models from Kerala and Bihar, with operational research contributions from International Centre for Diarrhoeal Disease Research, Bangladesh. Africa: The African Region saw dramatic declines through coordinated efforts by African Union, Nigeria federal and state health programs, and cross-border initiatives with neighboring states like Chad and Cameroon. Middle East: Outbreak responses in Syria and Iraq involved humanitarian coordination with UN OCHA and immunization days in refugee settings such as camps in Jordan and Lebanon. Pakistan and Afghanistan: Persistent transmission in Federally Administered Tribal Areas and provinces like Khyber Pakhtunkhwa required negotiation with local leaders and engagement with organizations including International Committee of the Red Cross.

Future strategies and legacy implications

Future strategies emphasize novel vaccine deployment from developers such as research consortia at Oxford University and manufacturing partnerships with GlaxoSmithKline and Sanofi Pasteur, expanded environmental surveillance exemplified by programs in Netherlands, and integration with broader child health initiatives promoted by UNICEF and WHO. Legacy implications include strengthened routine immunization systems informing responses to COVID-19 pandemic, workforce and laboratory capacity contributing to surveillance for pathogens studied at Johns Hopkins Bloomberg School of Public Health and Imperial College London, and policy precedents for eradication campaigns akin to Smallpox eradication that continue to influence global health governance in forums like the World Health Assembly and G20.

Category:Poliomyelitis Category:Public health